1 ONJ appears to be time-dependent with higher risk after
2 ONJ associated with IV bisphosphonate therapy is extreme
3 ONJ occurred posterior to the cuspids (n = 20) mostly in
4 ONJ prevents the jawbone from healing properly, leading
5 ONJ resolved in 60 patients (62%), resolved and recurred
6 e, 1.14 AFF, 0.21 esophageal cancer and 0.
09 ONJ events per 1,000 person-years in the alendronate coh
7 We found
16 ONJ cases among 572,606 cohort members; seven additional
8 We enrolled
191 ONJ cases and 573 controls in 119 dental practices.
9 prospectively for a minimum 3.2 years
after ONJ.
10 geal cancer (HR 0.95, 95% CI 0.53-1.70),
and ONJ (HR 1.62, 95% CI 0.78-3.34).
11 Overall, 90 patients developed
confirmed ONJ, with cumulative incidence of 0.8% (95% CI, 0.5%-1.1
12 Cumulative incidence of
confirmed ONJ, defined as an area of exposed bone in the maxillofa
13 guide stratification of risk for
developing ONJ in patients with MBD receiving zoledronic acid.
14 The variables predictive of
developing ONJ were dental extraction (P = .009), treatment with pa
15 ered profile in wound-healing markers
during ONJ development.
16 ith recurrent/nonhealing than single-
episode ONJ (84% v 62%; P = .02).
17 either ZA or OPG-Fc in rats with
established ONJ did not lead to ONJ resolution.
18 development or in patients with
established ONJ to accelerate healing.
19 ctice-Based Research Network study
estimated ONJ incidence and odds ratios from bisphosphonate exposu
20 than 5 weeks were more likely to
experience ONJ than patients with planned dosing intervals of 5 wee
21 In the second
experiment,
ONJ was established and antiresorptives were discontinue
22 Risk factors
for ONJ were also examined.
23 xtractions were independent risk factors
for ONJ.
24 Treatment options
for ONJ range from management of symptomology to surgical re
25 ate with physicians to minimize the risk
for ONJ.
26 ons and suggests that the absolute risks
for ONJ from oral bisphosphonates is low.
27 were 15.5 (CI, 6.0-38.7) more likely to
have ONJ than non-exposed patients; however, the sparse numbe
28 ce of dental disease and tooth extraction
in ONJ pathogenesis and help delineate an altered profile i
29 were 62 men; the median age was 61 years
in ONJ patients and 58 years among the rest.
30 esorptives or saline, after which we
induced ONJ using periapical disease and tooth extraction.
31 Osteonecrosis of the
jaw (
ONJ) affects patients with cancer and metastatic bone di
32 The incidence of osteonecrosis of the
jaw (
ONJ) in the population is low, but specifics are unknown
33 Osteonecrosis of the
jaw (
ONJ), a side-effect of bisphosphonate therapy, is charac
34 al fracture (AFF), osteonecrosis of the
jaw (
ONJ), and esophageal cancer.
35 lation, bone pain, osteonecrosis of the
jaw (
ONJ), atypical fractures, and osteosarcoma.
36 ral fractures, and osteonecrosis of the
jaw (
ONJ), the pathophysiological mechanisms involved are not
37 n in patients with osteonecrosis of the
jaw (
ONJ).
38 nal development of osteonecrosis of the
jaw (
ONJ).
39 de a discussion of osteonecrosis of the
jaw (
ONJ).
40 weigh the risk for osteonecrosis of the
jaw (
ONJ).
41 Osteonecrosis of the
jaws (
ONJ) is a rare but severe complication of antiresorptive
42 Osteonecrosis of the
jaws (
ONJ), a severe side effect of antiresorptive medications
43 onate therapy and osteonecrosis of the
jaws (
ONJ), but neither causality nor specific risks for lesio
44 a "drug holiday," has been used for
managing ONJ patients.
45 ients with single, recurrent, and
nonhealing ONJ (P = .2).
46 , 60.7 to 84.2 months), 33 possible cases
of ONJ were reported, all in the zoledronate-treated patien
47 se and bone metabolism on the development
of ONJ-like lesions.
48 rmed as being consistent with a diagnosis
of ONJ, representing a cumulative incidence of 2.1% (95% CI
49 al, radiographic, and histologic features
of ONJ.
50 We report on the frequency
of ONJ and investigate oral health-related quality of life
51 r studies of the pathogenesis and healing
of ONJ are needed.
52 einitiating bisphosphonates after healing
of ONJ is a reasonable option in patients experiencing rela
53 e findings show, the cumulative incidence
of ONJ after 3 years was 2.8% in patients receiving zoledro
54 trial is associated with a low incidence
of ONJ but does not seem to adversely affect Oral-QoL.
55 ogate for rodents, OPG-Fc, in a rat model
of ONJ.
56 osed patients; however, the sparse number
of ONJ cases limits firm conclusions and suggests that the
57 All potential occurrences
of ONJ were reported as serious adverse events and centrall
58 A higher rate
of ONJ was associated with fewer total number of teeth (HR,
59 Higher risk
of ONJ began within 2 years of bisphosphonate initiation an
60 y of dosing were associated with the risk
of ONJ.
61 More than a third
of ONJ patients also suffered from long bone fractures (n =
62 Dental treatment
of ONJ should be conservative and provide relief to the pat
63 serious jaw condition called
osteonecrosis (
ONJ) increases significantly.
64 Dental procedures
preceded ONJ in 46 patients (47%) and were more common in those w
65 edures, such as tooth extraction, to
prevent ONJ development or in patients with established ONJ to a
66 Recurrent ONJ followed reinitiation of bisphosphonates in six of 1
67 r infections and four patients had
recurrent ONJ.
68 Committee also discusses measures
regarding ONJ.
69 Incidence of bisphosphonate-
related ONJ in osteoporosis patients is unclear, but several stu
70 Patients with
spontaneous ONJ have a higher risk of nonhealing and recurrence.
71 r to tooth extraction ameliorated
subsequent ONJ development.
72 tal extraction, including 12 patients in
the ONJ group.
73 Median time from MM diagnosis
to ONJ was 8.4 years for the whole group.
74 in rats with established ONJ did not lead
to ONJ resolution.
75 Oral and intravenous bisphosphonate-
treated ONJ sites had reduced numbers of basal epithelial progen
76 phosphonate use was strongly associated
with ONJ (odds ratios [OR] 299.5 {95%CI 70.0-1282.7} for intr
77 l disease have been strongly associated
with ONJ development.
78 R = 6.6 {1.6-26.6}) remained associated
with ONJ.
79 hosphonate use were strongly associated
with ONJ.
80 osis therapies and many adverse events,
with ONJ an exception.
81 sphosphonate use and other risk factors
with ONJ.
82 examined human tissue from individuals
with ONJ and non-bisphosphonate-treated control individuals t
83 portantly, human biopsies from patients
with ONJ showed similar findings.